Abstract
Objectives
Changes in lipid profiles, Lp(a) lipoprotein, and acute phase reactants are associated with early atherosclerosis in rheumatoid arthritis (RA). The associations of Lp(a) levels with atherosclerotic disorders, diabetes, RA, and renal diseases suggest that Lp(a) might be involved in autoimmune reactions.
Methods
Eighty-seven women with RA diagnosed according to American Rheumatism Association criteria (mean age 45.4±9.4 years) were recruited and 50 healthy women (mean age 44±10.7 years) included as a control group. Serum Lp(a), total cholesterol (TC), triglyceride (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and C-reactive protein levels were analyzed.
Results
In the RA and C groups, serum Lp(a) levels were 39.2±20.6 mg/dl and 14.8±9.7 mg/dl, respectively (P<0.001). The TC levels were 188.4±41.8 mg/dl and 185.3±19.3 mg/dl (P>0.05), TG levels were 124.5±50.1 mg/dl and 94.6±24.9 mg/dl (P<0.01), HDL-C levels were 40.0±7.4 mg/dl and 52.8±4.8 mg/dl (P<0.01), and LDL-C levels were 123.4±24.6 mg/dl and 113.3±21.1 mg/dl (P>0.05). While serum CRP levels showed a positive correlation with Lp(a), they correlated negatively with HDL-C levels (r=0.83 and P<0.0001, r=−0.49 and P<0.0001, respectively). It was meaningful that Lp(a) correlated negatively with serum HDL-C level (r=−0.36, P<0.001).
Conclusions
It is suggested that higher serum Lp(a), lower HDL-C, higher TG level, and a high ratio of TC/HDL-C might show high risk of atherosclerosis. Inflammation in RA may cause changes in HDL-C and Lp(a) metabolisms.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Although it is not yet known exactly, changes in lipid profiles, Lp(a) lipoprotein, and acute phase reactants are associated with early atherosclerosis in rheumatoid arthritis (RA). Coronary atherosclerosis and acute myocardial infarction are the most common causes of death in patients with RA [1, 2, 3, 4, 5]. Several complex mechanisms are responsible for dyslipidemia in these patients. Chronic inflammation process, immobilization, gastrointestinal and liver diseases, systemic complications, several inflammatory mediators, and drugs may affect the lipid metabolism [6, 7]. In recent years, associations of LP(a) with insulin release, RA, and renal diseases have suggested that Lp(a) might be involved in immunologic mechanisms [8]. The aim of this study was to evaluate the relations of serum lipids and Lp(a) levels with inflammation in RA patients.
Material and methods
Patients
Eighty-seven female patients with RA diagnosed according to American Rheumatism Association criteria [9] (mean age 45±9.4 years) and 50 healthy women (mean age 44±10.7 years) as a control group were studied in the Pamukkale University Medical Faculty departments of internal medicine and cardiology between January 2001 and December 2002. None of the patients with RA had been taking corticosteroids or disease-modifying antirheumatic drugs, and all of them were in the active phase of illness at the time of hospital admission. Some of the patients were diagnosed with RA for the first time at admission, and most had given up the drugs by themselves for unknown reasons and had taken none for at least 2 months. None of the RA patients had a history of angina pectoris, myocardial infarction, or interventional management for coronary artery disease. Also, their resting electrocardiograms were normal. As a control group, healthy subjects without hypertension, diabetes mellitus, or signs or symptoms of any heart disease or any known chronic disease were chosen. Their physical examinations and resting electrocardiograms were also normal.
Assays
Serum Lp(a), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and C-reactive protein (CRP) were measured after an overnight fast (at least 12 h), and TC/HDL-C and LDL-C/HDL-C ratios were calculated.
Serum TC, HDL-C, TG, and CRP levels of patients and controls were analyzed with commercial kits (Abbott, USA) using an autoanalyzer (Aeroset, USA). Also, serum very low-density lipoprotein cholesterol (VLDL-C) was measured as TG/5. LDL-C was calculated with the Friedewald formula (LDL-C = TC − HDL-C − VLDL-C), if the serum TG level was under 400 mg/dl. Serum Lp(a) was analyzed by the nephelometric method using a Beckman kit, and normal range was 0–30 mg/dl.
Statistics
Statistics were performed with the version 10.0 Statistical Package for Social Sciences program for Windows. Normality of variables was tested by the Kolmogorov-Smirnov test. Distribution of TC, TG, HDL-C, LDL-C, Lp(a), and CRP levels were not normal. Thus, a log transformation before statistical analyses of means was performed, and then Student’s t-, Pearson’s chi-squared, linear-by-linear association, and Pearson’s correlation tests were performed.
Results
The characteristics of the patients with RA are compared with those of healthy subjects in Table 1. Mean age was similar in the RA and control groups (45±9.4 years and 44±10.7 years, respectively) (P>0.05). In patients, serum Lp(a) levels were higher than in healthy subjects (39.2±20.6 mg/dl and 14.8±9.7 mg/dl, respectively) (P=0.001). Serum TC and LDL-C levels were not significantly different between the two groups—188.4±41.8 mg/dl and 185.3±19.3 mg/dl (P>0.05), and 123.4±24.6 mg/dl and 113.3±21.1 mg/dl (P>0.05) in patients and healthy subjects, respectively.
Serum TG levels were significantly higher in patients (124.5±50.1 mg/dl) than healthy subjects (94.6±24.9 mg/dl, P<0.001), while serum HDL-C levels were significantly lower (40.0±7.4 mg/dl) than in controls (52.8±4.8 mg/dl, P<0.001). In both patients and healthy subjects, the TC/HDL-C ratios were 4.7±1.5 and 3.5±0.7 (P<0.01) and LDL-C/HDL-C ratios were 3.1±1.2 and 2.1±0.7 (P<0.05), respectively.
Serum CRP levels were 7.1±4.2 mg/dl and 0.03±0.01 mg/dl in patients and healthy subjects and differed significantly (P<0.001). Erythrocyte sedimentation rates were 52.2±18.1 mm/h and 12.3±8.2 mm/h in patients and controls, and also significantly different (P<0.001).
Subgroups of serum Lp(a) and lipid ratios in patients and healthy subjects are shown in Table 2. Fifty-five patients (63.2%) and nine healthy subjects (18%) had Lp(a) levels of >30 mg/dl (P<0.001). Numbers of patients and healthy subjects were significantly different in subgroups of the TC/HDL-C ratio (P<0.001). In 11 patients with RA (12.6%) and 24 healthy subjects (48%), the TC/HDL-C ratios were under 3.5 (P<0.001) and in 52 patients (59.8%) and eight healthy subjects (16%) greater than 4.5 (P<0.001). Twenty-four patients (27.6%) and 18 healthy subjects (36%) showed these ratios between 3.5 and 4.5 (P<0.001). However, the numbers of patients and healthy subjects were similar according to the subgroups of the LDL-C/HDL-C ratio (P>0.05).
Correlations
Correlations between serum CRP and Lp(a) and HDL-C levels are shown in Fig. 1 and Fig. 2. Serum CRP levels correlated positively with Lp(a) (r=0.83, P=0.0001) and negatively with HDL-C (r=−0.49, P=0.0001). Serum CRP levels did not correlate with serum TC or TG levels (r=−0.05, P>0.05 and r=−0.17, P>0.05, respectively). The correlation between serum Lp(a) and HDL-C levels is shown in Fig. 3. Serum Lp(a) correlated negatively with HDL-C (r=−0.36, P=0.001).
Discussion
Coronary atherosclerosis and acute myocardial infarction are the most common causes of death in patients with RA. Changes in lipid profiles, Lp(a), and acute phase reactants are associated with early atherosclerosis in RA. In addition to high TC and LDL-C levels, it is well known that high Lp(a) and low HDL-C levels are independent determinants of atherosclerosis. In recent years, meta-analytic studies have shown that high serum TG was an independent atherogenic factor for coronary heart disease (CHD) [10].
The results of several studies on Lp(a) levels in RA patients are different and incompatible. Rantapää-Dahlqvist et al. found that the Lp(a) level in RA patients was higher than in healthy subjects; however, they did not establish any correlation between Lp(a) and CRP [8]. Lakatos et al. found higher TC and LDL-C levels and lower HDL-C and TG levels in RA patients than in healthy subjects [11]. Other investigators found that not only serum HDL-C and TG levels, but also TC and LDL-C levels were lower in RA patients than healthy subjects [12, 13, 14, 15, 16].
The mechanisms of dyslipoproteinemia in RA are not well known, and several hypotheses have been suggested [17, 18, 19, 20, 21, 22, 23, 24]. The chronic inflammation process, immobilization, gastrointestinal and liver diseases, systemic complications of chronic diseases, several inflammatory mediators, and drugs may effect lipid metabolism. In myocardial infarction, acute infectious disease, and in heavily burned subjects, Lp(a) levels were found lower, suggesting that Lp(a) metabolism might be responsible for the inflammation. Lp(a) was found to be involved in carbohydrate metabolism, and increased Lp(a) levels have been described in diabetic patients having clinical complications [25, 26]. It was shown that the rapidity of protein synthesis was decreased in active RA patients, and this decrease may depend on either liver response to inflammatory mediators or increased synthesis and secretion of acute phase reactants from the liver [27]. These mechanisms may change lipoprotein metabolism, as the liver is the organ most important to Lp(a) metabolism.
The effects of the inflammatory process on Lp(a) metabolism are unclear. It was suggested that increased synthesis and/or decreased destruction of Lp(a) or changes in Lp(a) distribution between intravascular and extravascular regions may cause dyslipoproteinemia in RA [25]. The Lp(a) contained sixfold more sialic acid than LDL-C, so it was suggested that in inflammation, Lp(a) synthesis increased in liver like the other acute phase reactants. Since the lipid contents of Lp(a) and LDL-C were similar, they might have similar mechanisms in atherogenesis. It is suggested that the reticuloendothelial system became overstimulated in active RA and then lipid elimination by scavenger receptors of macrophages increased. For that reason, Lp(a) may have a role as an important atherogenic factor [26, 28, 29, 30].
Rössner et al. found that the Lp(a) (settled pre-beta lipoprotein) level was higher in polyarthritis patients than a control group [31]. Lazarevic et al. established that serum TC, LDL-C, and HDL-C levels were lower and TG was higher in RA patients having antilipoprotein antibodies; and they explained that this dyslipoproteinemia might be due to the antilipoprotein antibodies [32]. Wallberg-Jonsson et al. showed that von Willebrand’s factor, plasminogen activator inhibitor-1, and also haptoglobin and triglycerides were significantly increased in patients with RA who later suffered from thromboembolic events registered in a 2-year follow-up period [33]. In our study, there were relatively higher levels of TG in the patient group, in contrast to most of the other studies. None of the subjects was taking any anti-inflammatory drug that could affect lipid metabolism at the time of the study, so those lipid anomalies might be directly effected by RA and the inflammatory process. Additionally, the different HDL-C levels between RA patients and healthy subjects might be due to physical inactivity in the former, because all of our study patients had active-phase RA and various degrees of physical inactivity.
In recent years, several studies have established that atherosclerosis is an inflammatory disease and associated with high serum CRP levels (especially high-sensitive CRP), which is a predictor of coronary heart disease (CHD) [26, 30]. However, mechanisms of the inflammatory process in atherosclerosis are complex and not known exactly. In our study, although we found no correlation between CRP and TC and TG, we showed the positive correlation between CRP and Lp(a) and also the negative correlation between CRP and HDL-C levels. As a result, the association between RA and atherosclerosis is strong, because both diseases are inflammatory systemic and metabolic disorders. Dyslipoproteinemia in RA includes lower HDL-C, higher Lp(a), and higher TG and is related to atherosclerosis. Since increased serum CRP levels correlated with higher Lp(a) and lower HDL-C, our study convinces us that atherosclerosis is an inflammatory disease.
References
Isomaki HA, Mutru O, Koota K (1975) Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 4:205–208
Abruzzo JL (1982) Rheumatoid arthritis and mortality. Arthritis Rheum 25:1020–1023
Prior P, Symmons DPM, Scott DL, Brown R, Hawkins CF (1984) Causes of death in rheumatoid arthritis. Br J Rheumatol 23:92–99
Mutro O, Laakso M, Isomaki H, Koota K (1985) Ten year mortality and causes of death in patients with rheumatoid arthritis. BMJ 290:1811–1813
Wallberg-Jonsson S, Cederfelt M, Rantapää-Dahlqvist S (2000) Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year follow up study. J Rheumatol 27:71–75
Scanu AM (1992) Lipoprotein (a): a genetic risk factor for premature coronary heart disease. JAMA 267:3326–3329
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. Am J Med 62:707–714
Rantapää-Dahlqvist S, Wallberg-Jonsson S, Dahlen G (1991) Lipoprotein (a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 50:366–368
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Assmann G, Schulte H, Cullen P (1997) New and classical risk factors-the Munster Heart study (PROCAM). Eur J Med Res 2:237–242
Lakatos J, Harsagyi A (1988) Serum total HDL, LDL cholesterol and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 21:93–96
Svensson K, Lithel H, Hallgren R, Selinus I, Vesby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Relativity to inflammatory activity. Arch Intern Med 147:1912–1916
Lorber M, Aviram M, Linn S, Scharf Y, Brook JG (1985) Hypocholesterolemia and abnormal high density lipoprotein in rheumatoid arthritis. Br J Rheumatol 24:250–255
Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, Song CH, Lee J (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701–1704
Asanuma Y, Kawai S, Aoshima H, Kaburaki J, Mizushima Y (1999) Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 42:443–447
Seriolo B, Accardo S, Cutolo M (1996) Lipoprotein (a) and other risk factors for thrombosis in rheumatoid arthritis. J Rheumatol 23:194–196
Seriolo B, Accardo S, Fasciolo D, Bertolini S, Cutolo M (1996) Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Clin Exp Rheumatol 14:593–599
Seriolo B, Accardo S, Fasciolo D, Sulli A, Bertolini S, Cutolo M (1995) Lipoprotein (a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis. Thromb Haemost 74:799–800
Dahlen GH, Boman J, Birgander LS, Lindblom B (1995) Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 114:165–174
Dahlen GH (1994) Indications of an autoimmune component in Lp(a) associated disorders. Eur J Immunogenet 21:301–312
Lee YH, Choi SJ, Ji JD, Seo HS, Song GG (2000) Lipoprotein (a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 19:324–325
Banks MJ, Kitas GD (1999) Lipoprotein (a) levels and atherosclerosis in rheumatoid arthritis: comment on the article by Asanuma et al. Arthritis Rheum 42:2491–2492
Wallberg-Jonsson S, Uddhammar A, Dahlen G, Rantapää-Dahlqvist S (1995) Lipoprotein (a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Scand J Clin Lab Invest 55:309–315
Dahlen GH (1994) Lp (a) lipoprotein in cardiovascular disease. Atherosclerosis 108:111–126
Ehnholm C, Garoff H, Renkonen O, Simons K (1972) Protein and carbohydrate composition of Lp(a) lipoprotein from human plasma. Biochemistry 11:3229
Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126
Magaro M, Altomonte L, Zoli A, Mirone L, Ruffini MP (1991) Serum lipid pattern and apolipoproteins (A-I and B-100) in active rheumatoid arthritis. Z Rheumatol 50:168–170
Gianturco SH, Bradley WA (1994) Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidol 5:313–315
Svensson K, Lithell H, Hallgren R, Selinus I, Vessby B (1987) Altered serum lipoproteins and enhanced lipoprotein elimination in patients with rheumatoid arthritis and other chronic inflammatory arthritides. I. Relationship to the inflammatory activity. Arch Intern Med 147:1912–1916
Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876–1890
Rossner S, Lofmark C (1977) Dyslipoproteinemia in patients with active chronic polyarthritis: a study on serum lipoproteins and triglycerides clearance (intravenous fat tolerance test). Atherosclerosis 28:41–52
Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391
Wallberg-Jonsson S, Dahlen GH, Nilsson TK, Ranby M, Rantapää-Dahlqvist S (1993) Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 12:318–324
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dursunoğlu, D., Evrengül, H., Polat, B. et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 25, 241–245 (2005). https://doi.org/10.1007/s00296-004-0438-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-004-0438-0